The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement.

Scientists say they have achieved a "first" in the development of drugs to treat Alzheimer's disease. In a study published in ...

Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer's ...

CADASIL is a brain disease involving genetic mutations, stroke, and dementia. Learn about symptom progression and ongoing ...

“This research is taking promising steps towards a new one-of-a-kind therapy which targets tau, a damaging protein in the ...

An FDA-approved synthetic THC significantly reduces agitation in Alzheimer's patients, improving treatment outcomes and ...

Researchers suggest that the way Alzheimer's reshapes our brains is as unique as our fingerprints, challenging long-held ...

Pulses of light and sound seem to have beneficial effects. But some argue it is too soon to market experimental devices.

Managing dementia in the complex landscape of neurological disorders stands out as a formidable challenge, affecting millions ...

An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...

Clinical trials are the final bridge to cross before a new treatment can reach patients. Though Alzheimer's disease affects individuals across cultural, ethnic, racial, and socioeconomic lines, ...

An FDA-approved synthetic version of THC (the main ingredient in cannabis) reduces agitation in patients with Alzheimer's ...